The evolution of targeted intra operative radiotherapy in early breast cancer
No Thumbnail Available
Authors
Das,Aparimita;Abdulkarim,Khadeer;Banerjee,Soirindhri;Kurmude,Riya;Tan,Joecelyn Kirani;Prusty,Lydia;Mahajan,Ishika;Ghose,Aruni;Tiwari,Aaditya;Kassamali,Abbas;Hasanova,Maryam;Chapagain,Pratima;Linares,Christian A.;Vaidya,Jayant S.;Boussios,Stergios
Check for full-text access
Issue Date
2025
Type
Article
Language
Keywords
Alternative Title
Abstract
Targeted intraoperative radiotherapy (IORT) delivers a single dose of radiation to a fresh tumour bed immediately after lumpectomy, commonly used to treat early breast cancer (EBC). It is delivered during the same sitting, with improved patient compliance and better sparing of adjacent healthy tissue, compared to conventional adjuvant radiotherapy to the whole breast. The recently published 12-year results (median follow up of 8.6 years) of the TARGIT-A trial offers reliable conclusions, of comparable oncological outcomes with a reduced toxicity profile supporting IORT as a replacement for whole breast external beam radiotherapy (EBRT) for suitable patients with EBC. Reduced need of multiple hospital visits is an added logistic advantage which makes IORT a cost-effective, less painful and cosmetically favourable alternative to standard EBRT, now included in several international guidelines with growing popularity among clinicians worldwide.
Description
Citation
Publisher
License
Journal
Journal of cancer research and clinical oncology
Volume
151
Issue
9